Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Propiomazine→

Propiomazine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
362-29-8
Molecular formula
C20H24N2OS
Molecular weight
340.5 g/mol
Drug class
Phenothiazine-related sedative-hypnotichistamine H1 and dopamine receptor antagonist
Mechanism of action
Produces sedation primarily through central histamine H1 receptor antagonism with additional dopamine and muscarinic receptor effects. The exact mechanism in insomnia is not fully established.
Indications / reported uses
  • Short-term symptomatic treatment of insomnia in countries where propiomazine products are authorised; not a treatment for chronic insomnia without assessment of underlying causes

Sources: NLM MeSH — Propiomazine · PubMed — Propiomazine hypnotic pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Propiomazine Environmental Risk Assessment (ERA) (the Propiomazine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.